Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 2/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.51 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.51 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1770451 | 0.95 | CA2 (0.51) | CA2CA1CA12CA9KMT2A | |
| SCHEMBL950400 | 0.85 | SNCA (0.59) | CA2CA1CA12CA9KMT2A | |
| SCHEMBL28865482 | 0.84 | CA1 (0.67) | CA2CA1CA12CA9KMT2A | |
| SCHEMBL58191 | 0.84 | CA1 (0.67) | CA2CA1CA12CA9KMT2A | |
| SCHEMBL8577441 | 0.84 | MEN1 (0.68) | CA2CA1CA12CA9KMT2A | |
| SCHEMBL8784476 | 0.83 | CA2 (0.53) | CA2CA1CA12CA9KMT2A | |
| SCHEMBL8784484 | 0.83 | SNCA (0.58) | CA2CA1CA12CA9KMT2A | |
| Water SCHEMBL11035834 | 0.83 | SNCA (0.58) | CA2CA1CA12CA9KMT2A | |
| SCHEMBL6124914 | 0.82 | ALDH1A1 (0.44) | CA2CA1CA12CA9KMT2A | |
| SCHEMBL6077871 | 0.81 | CA2 (0.59) | CA2CA1CA12CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318361-B1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-8841291-B2 | Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors | NOVARTIS AG (CH) | 2014-09-23 | — | — | US | disclosed |
| US-20140031399-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2014-01-30 | — | — | US | disclosed |
| US-8419849-B2 | Disazo dyes and their use in ink-jet printing | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2013-04-16 | — | — | US | disclosed |
| EP-2344589-B1 | DISAZO COMPOUNDS AND THEIR USE IN INK-JET PRINTING | FUJIFILM IMAGING COLORANTS LTD (GB) | 2013-01-16 | — | — | EP | disclosed |
| CN-102143942-A | Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors | NOVARTIS AG | 2011-08-03 | — | — | CN | disclosed |
| US-20110112076-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2011-05-12 | — | — | US | disclosed |
| EP-2318361-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | Novartis AG (CH) | 2011-05-11 | — | — | EP | disclosed |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| WO-2010007027-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-5378715-A | Sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0558258-A1 | N-isoxazole-naphthylsulfonamide derivatives and their use as endothelin antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-09-01 | — | — | EP | disclosed |
| US-5202339-A | Hypoglycemic, hypolipedemic agents | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1993-04-13 | — | — | US | disclosed |
| EP-0511152-A2 | Quinoxaline compounds, their preparation and use | NOVO NORDISK A/S (DK) | 1992-10-28 | — | — | EP | disclosed |
| EP-0305947-B1 | HYDANTOIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS WELL AS THEIR USE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1992-07-29 | — | — | EP | disclosed |
| US-5004751-A | Antidiabetic agents; aldoe reductase inhibitors | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1991-04-02 | — | — | US | disclosed |
| US-4914099-A | TREATMENT OR PREVENTION OF DIABETIC COMPLICATIONS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1990-04-03 | — | — | US | disclosed |
| WO-1989001934-A1 | HYDANTOIN DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1989-03-09 | — | — | WO | disclosed |
| EP-0305947-A1 | Hydantoin derivatives, process for their preparation and pharmaceutical compositions containing the same as well as their use | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1989-03-08 | — | — | EP | disclosed |
| US-4487725-A | Process for the preparation of N-acetylaminoarylsulfonic acids in sulfuric acid as solvent | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112076-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | MMP13, MMP11, MMP14 | CA2 177/4885CA1 123/4885CA12 42/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | CA2 3237/4885CA1 3593/4885CA12 4499/4885 |
| US-20140031399-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | MMP13, MMP11, MMP14 | CA2 179/4885CA1 124/4885CA12 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.